help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on September 13, 2007, doi:10.1164/rccm.200701-085OC

Am. J. Respir. Crit. Care Med., Volume 176, Number 11, December 2007, 1062-1071

A more recent version of this article appeared on December 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200701-085OCv1
176/11/1062    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flood-Page, P.
Right arrow Articles by Barnes, N. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flood-Page, P.
Right arrow Articles by Barnes, N. C

Submitted on January 16, 2007
Accepted on September 13, 2007

A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma

Patrick Flood-Page1, Cheri Swenson2, Isidore Faiferman3, John Matthews3, Michael Williams3, Lesley Brannick3, Douglas Robinson4, Sally Wenzel5, William Busse2, Trevor T Hansel4, and Neil C Barnes6*

1 Royal Gwent Hospital, Newport, United Kingdom, 2 Allergy and Asthma Clinical Research Unit, University of Wisconsin-Madison, Madison, WI, USA, 3 Respiratory and Inflammation Discovery Medicine, GlaxoSmithKline, Greenford, United Kingdom, 4 NHLI, Imperial College London, London, United Kingdom, 5 National Jewish Medical and Research Center, Denver, CO, USA, 6 London Chest Hospital, London, United Kingdom

* To whom correspondence should be addressed. E-mail: neil.barnes{at}bartsandthelondon.nhs.uk.

Rationale: Accumulation of eosinophils in the bronchial mucosa of individuals with asthma is considered to be a central event in the pathogenesis of asthma. In animal models, airway eosinophil recruitment and airway hyper-responsiveness in response to allergen challenge are reduced by specific targeting of interleukin-5. A previous small dose-finding study found that mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, had no effect on allergen challenge in humans. Objective: To investigate the effect of three intravenous infusions of mepolizumab 250 mg or 750 mg at monthly intervals on clinical outcome measures in 362 patients with asthma experiencing persistent symptoms despite inhaled corticosteroid therapy (400-1000 µg beclomethasone or equivalent). Method: Multicenter, randomized, double-blind, placebo-controlled study. Measures: Morning peak expiratory flow, forced expiratory volume in 1 second, daily {beta}2-agonist use, symptom scores, exacerbation rates and quality of life measures. Sputum eosinophil levels were also measured in a subgroup of 37 individuals. Main results: Mepolizumab was associated with a significant reduction in blood and sputum eosinophils in both treatment groups (blood: p<0.001 for both doses; sputum: p=0.006 for 250 mg and p=0.004 for 750 mg). There were no statistically significant changes in any of the clinical endpoints measured. There was a non-significant trend for decrease in exacerbation rates in the mepolizumab 750 mg treatment group (p=0.065). Conclusions: Mepolizumab treatment does not appear to add significant clinical benefit in asthmatic patients with persistent symptoms despite inhaled corticosteroid therapy. Further studies are needed to investigate the effect of mepolizumab on exacerbation rates using protocols specifically tailored to asthmatics with persistent airway eosinophilia.
Key words: asthma, eosinophils, anti-interleukin-5, monoclonal antibodies, mepolizumab




This article has been cited by other articles:


Home page
 CMAJHome page
K. R. Chapman and A. McIvor
Asthma that is unresponsive to usual care
Can. Med. Assoc. J., January 12, 2010; 182(1): 45 - 52.
[Full Text] [PDF]

Home page
 Int ImmunolHome page
T. Kouro and K. Takatsu
IL-5- and eosinophil-mediated inflammation: from discovery to therapy
Int. Immunol., December 1, 2009; 21(12): 1303 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Song, J. Y. Cho, S. Y. Lee, M. Miller, P. Rosenthal, P. Soroosh, M. Croft, M. Zhang, A. Varki, and D. H. Broide
Anti-Siglec-F Antibody Reduces Allergen-Induced Eosinophilic Inflammation and Airway Remodeling
J. Immunol., October 15, 2009; 183(8): 5333 - 5341.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. G. Woodruff, B. Modrek, D. F. Choy, G. Jia, A. R. Abbas, A. Ellwanger, J. R. Arron, L. L. Koth, and J. V. Fahy
T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma
Am. J. Respir. Crit. Care Med., September 1, 2009; 180(5): 388 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. I. Caceres, M. Brackmann, M. D. Elia, B. F. Bessac, D. del Camino, M. D'Amours, J. S. Witek, C. M. Fanger, J. A. Chong, N. J. Hayward, et al.
A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma
PNAS, June 2, 2009; 106(22): 9099 - 9104.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
M. Humbert
Biologics in severe difficult-to-treat asthma: find the right niche!
Eur. Respir. Rev., June 1, 2009; 18(112): 51 - 53.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. F. Lemanske Jr.
Asthma Therapies Revisited: What Have We Learned?
Proceedings of the ATS, May 1, 2009; 6(3): 312 - 315.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Haldar, C. E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, R. P. Marshall, P. Bradding, R. H. Green, A. J. Wardlaw, et al.
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
N. Engl. J. Med., March 5, 2009; 360(10): 973 - 984.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Nair, M. M.M. Pizzichini, M. Kjarsgaard, M. D. Inman, A. Efthimiadis, E. Pizzichini, F. E. Hargreave, and P. M. O'Byrne
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
N. Engl. J. Med., March 5, 2009; 360(10): 985 - 993.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Wenzel
Eosinophils in Asthma -- Closing the Loop or Opening the Door?
N. Engl. J. Med., March 5, 2009; 360(10): 1026 - 1028.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. C. Moore
Update in Asthma 2007
Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1068 - 1073.
[Full Text] [PDF]

Home page
 NEJMHome page
M. E. Wechsler
Combating the Eosinophil with Anti-Interleukin-5 Therapy
N. Engl. J. Med., March 20, 2008; 358(12): 1293 - 1294.
[Full Text] [PDF]

Home page
 JEMHome page
E. A. Jacobsen, S. I. Ochkur, R. S. Pero, A. G. Taranova, C. A. Protheroe, D. C. Colbert, N. A. Lee, and J. J. Lee
Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells
J. Exp. Med., March 17, 2008; 205(3): 699 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. M. O'Byrne
The Demise of Anti IL-5 for Asthma, or Not
Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1059 - 1060.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society 		  Work-Life